"Abbott Laboratories (ABT) split into two companies at the start of the year, a medical products business that retained the Abbott name and a proprietary drug business called AbbVie (ABBV). I am aware of many dividend growth investors who sold pre- or post-split, but I decided to hold. It turned out to be a good decision, with AbbVie's stock experiencing a large capital gain and Abbott announcing a 57% dividend increase for 2014."
I won't short it yet......the original poster called it a dog....reasonable question to that post is: if it's a dog why not short it? I'll short it (sell covered call options) when it's overpriced. It's not over priced yet. Read my post "anticipation" for the reasons not to short now.